Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit

Annals of Surgical Oncology

Volumn 10, Issue 8, 2003, Pages 898-902

  Kodera, Yasuhiro ^a   Ito, Seiji ^b   Yamamura, Yoshitaka ^b   Mochizuki, Yoshinari ^b   Fujiwara, Michitaka ^a   Hibi, Kenji ^a   Ito, Katsuki ^a   Akiyama, Seiji ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cancer recurrence; Curative resection; Follow up; Gastrectomy; Gastric carcinoma

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; METASTASIS; PATIENT MONITORING; STATISTICAL SIGNIFICANCE; STOMACH CANCER; TREATMENT OUTCOME; CHI SQUARE DISTRIBUTION; HEALTH SURVEY; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; STOMACH TUMOR; SURVIVAL; TUMOR RECURRENCE;

CHI-SQUARE DISTRIBUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; STATISTICS, NONPARAMETRIC; STOMACH NEOPLASMS; SURVIVAL ANALYSIS;

EID: 1542754779     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1245/ASO.2003.12.009     Document Type: Article

References (13)

1. Gunderson LL, Donohue JH, Burch PA. Stomach. In: Abeloff MD, Armitage JO, Lichter AS, eds. Clinical Oncology. New York: Churchill Livingstone, 1995:1209-41.
2. Boehner H, Zimmer T, Hopfenmueller W, Berger G, Buhr HJ. Detection and prognosis of recurrent gastric cancer - is routine follow-up after gastrectomy worthwhile? Hepatogastroenterology 2000;47:1489-94.
3. NCCN practice guidelines for upper gastrointestinal carcinomas. National Comprehensive Cancer Network. Oncology (Huntingt) 1998;12:179-223.
4. Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours. 5th ed. New York: Wiley, 1997.
5. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 1993;72:37-41.
6. Glimelius B, Ekstrom K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997;8:163-8.
7. Pyrhoenen S, Kuitunen T, Nyandoto P, Kouri M. Randomized comparison of 5-fluorouracil, epidoxorabicin, and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 1995;71:587-91.
8. Boku N, Ohtsu A, Shimada Y, et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 1999;17:319-23.
9. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 in advanced gastric cancer patients. Eur J Cancer 1998;34:1715-20.
10. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-42.
11. Howell JD, Wotherspoon H, Leen E, Cooke TC, McArdle CS. Evaluation of a follow-up programme after curative resection for colorectal cancer. Br J Cancer 1999;79:308-10.
12. Yasui K, Hirai T, Kato T, et al. A new macroscopic classification predicts prognosis for patients with liver metastases from colorectal cancer. Ann Surg 1997;226:582-6.
13. Saiura A, Umekita N, Inoue S, et al. Clinicopathological features and outcome of hepatic resection for liver metastasis from gastric cancer. Hepatogastroenterology 2002;49:1062-5.